NASDAQ$ZYME
Zymeworks Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Zymeworks reported Q1 2025 revenue of C$45.0M, a net loss of C$23.0M, diluted EPS of $(0.30).
For Q1 2025, Zymeworks reported Revenue was C$45.0M, net loss was C$23.0M, diluted EPS was $-0.30. Management discusses operating trends, liquidity, and outlook in the quarterly filing.
- Revenue C$45.0M for Q1 2025.
- Net loss C$23.0M.
- Diluted EPS $-0.30.
Headline financials
Revenue & EPS history
Zymeworks · Revenue · Quarterly
$27.1M
Forward guidance
Management emphasizes path to profitability, liquidity, and cost discipline.
Tailwinds
- Operating initiatives and partnership milestones.
- Cash runway supports near-term plans.
Headwinds
- Operating losses and financing needs.
- Macro and competitive uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q1 2025
-1.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.6%
Avg return
30 days after
38%
5 / 13 earnings
Positive
+1.4%
Q1 2023
Best reaction
-8.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.6% | -13.5% | -13.0% | |
| Q4 2025 | +0.1% | +3.4% | +11.4% | |
| Q3 2025 | -8.0% | +8.2% | +49.1% | |
| Q1 2025 | -0.1% | -0.6% | +11.3% | |
| Q4 2024 | -8.0% | -11.2% | -16.9% | |
| Q3 2024 | +1.0% | +1.2% | +11.7% | |
| Q2 2024 | +0.0% | +4.3% | +22.4% | |
| Q1 2024 | +0.0% | -8.3% | -18.4% | |
| Q4 2023 | +0.0% | +1.6% | +3.8% | |
| Q3 2023 | +1.2% | +0.1% | +31.2% | |
| Q3 2021 | +0.0% | -1.3% | +10.3% | |
| Q2 2023 | +0.8% | -3.6% | -7.5% | |
| Q1 2023 | +1.4% | +14.1% | +2.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro